PMC6083596_01
Patient 1. Trend of the mean deviation (MD) from January 2014 to September 2016. The arrow indicates the beginning of treatment with CBS eye drop. RE: right eye; LE: left eye.
CRIOPM2018-2381296.001.jpg
PMC6083596_01_CRIOPM2018-2381296.001.jpg
fig1
In Figure 1 the mean deviation (MD) values recorded in January 2014, June 2016, and September 2016 were graphed.
Patient 1. Central 30-2 visual field test recorded in June 2016 (a, b) and September 2016 (c,d), in right (RE) and left (LE) eye.
CRIOPM2018-2381296.002.jpg
PMC6083596_01_CRIOPM2018-2381296.002.jpg
fig2
In Figure 2 the central 30-2 visual field tests before ((a) right eye RE; (b) left eye LE) and after (c, d) the CBS treatment were shown.
PMC6083596_02
Ten-year trend of the mean deviation (MD), from December 2006 to September 2016. The arrow indicates the beginning of treatment with CBS eye drop. RE: right eye; LE: left eye.
CRIOPM2018-2381296.003.jpg
PMC6083596_02_CRIOPM2018-2381296.003.jpg
fig3
In Figure 3 the mean deviation (MD) values recorded over several visits performed from December 2006 through September 2016 were graphed.
Ten-year trend of the Pattern Standard Deviation (PSD), from December 2006 to September 2016. The arrow indicates the beginning of treatment with CBS eye drop. RE: right eye; LE: left eye.
CRIOPM2018-2381296.004.jpg
PMC6083596_02_CRIOPM2018-2381296.004.jpg
fig4
The improvement is also demonstrated by the analysis of the PSD shown in Figure 4.
Patient 2. Central 30-2 visual field test recorded in March 2016 (a, b) before the start of CBS treatment, June 2016 (c,d) at the end of CBS treatment, and September 2016 (e, f) after four months from the end of CBS treatment, in right (RE) and left (LE) eye.
CRIOPM2018-2381296.005.jpg
PMC6083596_02_CRIOPM2018-2381296.005.jpg
fig5
In Figure 5 the central 30-2 visual field tests before ((a): right eye RE; (b): left eye LE), at the end (c, d) and after four months (e, f) from the end of the CBS eye drop treatment were shown.